Market Cap (In SEK)
180.25 Million
Revenue (In SEK)
8.01 Million
Net Income (In SEK)
-102.85 Million
Avg. Volume
94.87 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.0-6.92
- PE
- -
- EPS
- -
- Beta Value
- 0.623
- ISIN
- SE0009607252
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jonas Sohlman
- Employee Count
- -
- Website
- https://www.intervacc.se
- Ipo Date
- 2017-04-07
- Details
- Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
More Stocks
-
7815
-
4716
-
ALSOGSogeclair SA
ALSOG
-
JXJT
-
3836Avant Corporation
3836
-
SUPERHOUSESuperhouse Limited
SUPERHOUSE
-
3015FSP Technology Inc.
3015
-
ATT